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Experimental Procedures 
Materials 
All canonical amino acids and (4S)-1,3-thiazolidine-4-carboxylic acid (Thz) were purchased from Sigma.  
(S)-azetidine-2-carboxylic acid (Aze) and (3,4)-dehydro-L-proline (Dhp) were purchased from Bachem 
Americas.  (S)-piperidine-2-carboxylic acid (Pip) was purchased from TCI America under the chemical name 
L-pipecolic acid.  All solutions and buffers were made using double-distilled water (ddH2O). 
Strains and plasmids 
A gene encoding proinsulin (PI) bearing an N-terminal hexahistidine tag (6xHis) and flanked by EcoR1 and 
BamH1 restriction sites was ordered as a gBlock from Integrated DNA Technologies. The gBlock and 
plasmid vector pQE80L (which allows IPTG-inducible gene expression) were digested with EcoRI and 
BamHI.  Linearized pQE80L was dephosphorylated by treatment with alkaline phosphatase (NEB). Ligation 
of the digested PI gene and linearized vector yielded plasmid pQE80PI (which was used to produce ProI). 
To make plasmid pQE80PI-proS, genomic DNA was extracted from E. coli strain DH10B using DNeasy Blood 
and Tissue Kit (Qiagen). Primers (Integrated DNA Technologies) were designed to amplify the E. coli proS 
gene, encoding prolyl-tRNA synthetase, under constitutive control of its endogenous promoter, from 
purified genomic DNA, and to append NheI and NcoI sites. The digested proS gene was then inserted into 
pQE80PI between transcription termination sites by ligation at NheI and NcoI restriction sites. Site-
directed mutagenesis of pQE80PI-proS at the site corresponding to a cysteine at position 443 was 
performed to make plasmid pQE80PI-proS(C443G), which differs from pQE80PI-proS by one nucleotide 
that specifies a single amino acid mutation to glycine. Prototrophic E. coli strain JT31 and proline-
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auxotrophic E. coli strain CAG18515 were obtained from the Coli Genetic Stock Center at Yale University. 
JT31, containing a deletion for proline dehydrogenase (which is known to degrade Dhp and Thz),1-2 was 
made proline-auxotrophic by deleting the gene proA using λ Red-mediated recombination3; the new strain 
was designated KS32. CAG18515 was used for the expression of AzeI and PipI, while KS32 was used for 
the expression of DhpI and ThzI. Prototrophic E. coli strain BL21 was used for expression of canonical 
insulins (ProI, AspI) in rich media. Site-directed mutagenesis of pQE80PI at the site corresponding to 
insulin B28 was performed to make plasmid pQE80PI-asp, which differs from pQE80PI by three 
nucleotides that specify a single amino acid mutation to aspartic acid. All genes and plasmids were 
confirmed by DNA sequencing. 
Protein expression 
Plasmids pQE80PI and pQE80PI-asp were transformed into BL21 cells and grown on ampicillin-selective 
agar plates. A single colony was used to inoculate 5 mL of Luria-Bertani (LB) medium and grown overnight; 
the resulting saturated culture was used to inoculate another 1 L of LB medium. All expression 
experiments were conducted at 37°C, 200 RPM in shake flasks (Fernbach 2.8 L flasks, Pyrex®). Each culture 
was induced with 1 mM IPTG at mid-exponential phase (OD600 ~0.8). For incorporation of the proline 
analogs (Aze, Dhp, Thz, and Pip), pQE80PI-proS was transformed into both cell strains (CAG18515 and 
KS32) and pQE80-proS (C443G) was transformed into the CAG18515 cell strain. All cells were grown on 
ampicillin-selective agar plates. A single colony was used to inoculate 25 mL of LB medium and the culture 
was grown overnight prior to dilution into 1 L of 1X M9, 20 aa medium (8.5 mM NaCl, 18.7 mM NH4Cl, 22 
mM KH2PO4, 47.8 mM Na2HPO4, 0.1 mM CaCl2, 1 mM MgSO4, 3 mg/L FeSO4, 1 μg/L of trace metals (Cu2+, 
Mn2+, Zn2+, MoO42-), 35 mg/L thiamine hydrochloride, 10 mg/L biotin, 20 mM D-glucose, 200 mg/L 
ampicillin with 50 mg/L of L-amino acids, each). At a cell density corresponding to OD600 ~0.8, the culture 
was subjected to a medium shift; briefly, cells were centrifuged and washed with saline prior to 
resuspension in 0.8 L of 1.25X M9, 19 aa (1X M9, 20 aa medium without L-proline). After cells were further 
incubated for 30 min to deplete intracellular proline, 200 mL of 5X additives (1.5 M NaCl, 2.5 mM Aze, 
Dhp, Thz, or Pip) was added to the culture. After another 15 min of incubation at 37°C to allow amino acid 
uptake prior to induction, IPTG was added to a final concentration of 1 mM. After 2 h, cells were harvested 
by centrifugation and stored at -80°C until further use.  
Cell lysis and refolding from inclusion bodies 
Cells were thawed on the benchtop for 15 min prior to resuspension in lysis buffer (B-PER®, 0.5 mg/mL 
lysozyme, 50 U/mL benzonase nuclease). Cells were gently agitated at RT for 1 h prior to centrifugation 
(10 000 g, 10 min, RT); supernatant was discarded, and the pellet was washed thrice: once with wash 
buffer (2 M urea, 20 mM Tris, 1% Triton X-100, pH 8.0) and twice with sterile ddH2O; centrifugation 
followed each wash and the supernatant was discarded. The final washed pellet containing inclusion 
bodies (IBs, ~50% PI) was re-suspended in Ni-NTA binding buffer (8 M urea, 300 mM NaCl, 50 mM 
NaH2PO4, pH 8.0) overnight at 4°C or at RT for 2 h, both with gentle agitation. The suspension was 
centrifuged to remove insoluble debris, the remaining pellet was discarded, and the supernatant was 
mixed with pre-equilibrated Ni-NTA resin (Qiagen) at RT for 1 h to purify PI from the IB fraction. Unbound 
proteins in the IB fraction were collected in the flow-through (FT), and the resin was washed with Ni-NTA 
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wash (W) buffer (8 M urea, 20 mM Tris base, 5 mM imidazole, pH 8.0) and Ni-NTA rinse buffer (8 M urea, 
20 mM Tris base, pH 8.0) to remove any remaining non-specific proteins still bound to the resin. Finally, 
PI was stripped from the resin with Ni-NTA elution buffer (8 M urea, 20 mM Tris base, pH 3.0).  Fractions 
(IBs, FT, W, elution) were collected and run under reducing conditions on SDS-PAGE (Bis/Tris gels, 
Novex®); elution fractions containing PI were pooled and solution pH was adjusted to 9.6 with 6 N NaOH 
in preparation for oxidative sulfitolysis. Oxidative sulfitolysis was performed at RT for 4 h, with the 
addition of sodium sulfite and sodium tetrathionate (0.2 M Na2SO3, 0.02 M Na2S4O6); the reaction was 
quenched by 10-fold dilution with ddH2O. To isolate PI from the quenched solution, the pH was adjusted 
to between 3.5 and 4.5 by adding 6 N HCl dropwise; the solution became cloudy. The solution was 
centrifuged (10 000 g, 10 min, RT) and supernatant discarded. The PI pellet was then re-suspended in 
refolding buffer (0.3 M urea, 50 mM glycine, pH 10.6) and protein concentration was estimated by the 
bicinchoninic acid assay (BCA assay, Pierce®). The concentration of PI was adjusted to 0.5 mg/mL. 
Refolding was initiated by addition of β-mercaptoethanol to a final concentration of 0.5 mM and allowed 
to proceed at 12°C overnight with gentle agitation (New Brunswick® shaker, 100 RPM). Post-refolding, 
soluble PI was harvested by adjusting the pH of the solution to 4-5 by dropwise addition of 6 N HCl and by 
high speed centrifugation to remove insoluble proteins. The supernatant was adjusted to pH 8–8.5 by 
dropwise addition of 6 N NaOH and dialyzed against fresh PI dialysis buffer (7.5 mM sodium phosphate 
buffer, pH 8.0) at 4°C with five buffer changes to remove urea. The retentate (PI in dialysis buffer) was 
then lyophilized and subsequently stored at -80°C until further processing. Typical yields were 20–50 mg 
PI per L of culture (20–30 mg/L for non-canonical PI, 40–50 mg/L for canonical PI expression in rich media). 
Proteolysis and chromatographic (HPLC) purification  
The dry PI powder was re-dissolved in water to a final concentration of 5 mg/mL PI (final concentration of 
sodium phosphate buffer was 100 mM, pH 8.0). Trypsin (Sigma-Aldrich) and carboxypeptidase-B 
(Worthington Biochemical) were added to final concentrations of 20 U/mL and 10 U/mL, respectively, to 
initiate proteolytic cleavage. The PI/protease solution was incubated at 37°C for 2.5 h; proteolysis was 
quenched by addition of 0.1% trifluoroacetic acid (TFA) and dilute HCl to adjust the pH to 4. Matured 
insulin was purified by reversed phase high-performance liquid chromatography (HPLC) on a C18 column 
using a gradient mobile phase of 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (ACN; solvent 
B). Elution was carried from 0% B to 39% B with a gradient of 0.25% B per min during peak elution. 
Fractions were collected and lyophilized, and the dry powder was dissolved in 10 mM sodium phosphate, 
pH 8.0. Insulin-containing fractions were verified by matrix-assisted laser desorption/ionization-mass 
spectrometry (MALDI-MS; Voyager MALDI-TOF, Applied Biosystems) and SDS-PAGE to ensure identity and 
purity. Typical yields were 5-20 mg insulin per 100 mg PI. Fractions were stored at -80°C in 10 mM 
phosphate buffer, pH 8.0 until further use. 
Verification of Aze, Dhp, Thz, and Pip incorporation levels and maturation 
A 30 μL aliquot of PI solution (8 M urea, 20 mM Tris, pH 8) was subjected to cysteine reduction and 
alkylation (5 mM DTT, 55°C, 20 min; 15 mM iodoacetamide, RT, 15 min, dark) prior to 10-fold dilution into 
100 mM NH4HCO3, pH 8.0 (100 μL final volume).  Peptide digestion was initiated with 0.6 μL of gluC stock 
solution (reconstituted at 0.5 μg/μL with ddH2O, Promega) at 37°C for 2.5 h. The reaction was quenched 
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by addition of 10 μL 5% TFA and immediately subjected to C18 ZipTip (Millipore) peptide purification and 
desalting according to the manufacturer’s protocol. Peptides were eluted in 50% ACN, 0.1% TFA; the 
eluent was then diluted 3-fold into matrix solution (saturated α-cyanohydroxycinnamic acid in 50% ACN, 
0.1% TFA) and analyzed by mass spectrometry (Voyager MALDI-TOF, Applied Biosystems). Incorporation 
levels were analyzed prior to and after refolding; incorporation percentage was calculated by comparing 
total AUC (area under the curve, arbitrary units) of the non-canonical peak (expected m/z: 1543 Da for 
the proinsulin peptide containing AzeB28 [-14 Da], 1555 Da for DhpB28 [-2 Da], 1573 for ThzB28 [+16 Da], 
or 1571 for PipB28 [+14 Da]; 5794 Da for intact AzeI, 5806 Da for DhpI, 5824 for ThzI, or 5822 Da for PipI) 
with total AUC of its canonical counterpart (1557 Da and 5808 Da for ProI, respectively). Maturation of 
AzeI, DhpI, ThzI, and PipI was analyzed after HPLC purification. TFA (1.6 μL, 5%) was added to 15 μL mature 
insulin solution (10 mM phosphate buffer pH 8.0) and subjected to C18 ZipTip (Millipore) peptide 
purification and desalting per the manufacturer’s protocol. 
Circular dichroism 
Spectra were collected on samples contained in 1-cm quartz cuvettes in 10 mM sodium phosphate buffer 
pH 8.0. Data were collected from 195 nm to 250 nm, with step size of 0.25 nm and averaging time of 1 s 
on a Model 410 Aviv Circular Dichroism Spectrophotometer; spectra were averaged over 3 repeat scans. 
A reference buffer spectrum was subtracted from the sample spectra for conversion to mean residue 
ellipticity. The insulin concentration was 60 µM. 
Hexamer dissociation assay 
Insulins were quantified by both UV absorbance (NanoDrop Lite, ThermoFisher) and BCA assay, and 
normalized to 125 μM insulin prior to dialysis against 50 mM Tris/perchlorate, 25 μM zinc sulfate, pH 8.0 
overnight at 4°C using a D-tube dialyzer (Millipore Corp.) with MWCO of 3.5 kDa.  Aliquots of dialyzed 
insulin solution were mixed with phenol to yield samples of the following composition: 100 μM insulin, 
20 μM zinc sulfate, 100 mM phenol. Dissociation was initiated by the addition of terpyridine (terpy; 
Sigma-Aldrich) to a final concentration of 0.3 mM from a 0.75 mM stock solution. A Varioskan multimode 
plate reader (ThermoScientific) was used to detect the appearance of the Zn2+-(terpy) complex by 
monitoring absorbance at 334 nm. The data were fitted to a mono-exponential function using Origin 
software (OriginLab). The function was of the form: A334 (t) = A334 (t = ∞) – Ae–(t/𝜏½), where A is a fitting 
constant, A334 (t) is the absorbance at 334 nm at time t and A334 (t = ∞) is the long-time, asymptotic value 
of A334 (t). The value of A334 (t = ∞) – A334 (t) is proportional to the concentration of insulin hexamer at 
time t. Kinetic runs were done at least in triplicate. Post-assay insulin samples were pooled, and sample 
quality was determined by SDS-PAGE. 
Fibrillation assay 
Insulin samples (60 μM in 10 mM phosphate, pH 8.0) were centrifuged at 22 000 g for 1 h immediately 
after addition of thioflavin T (ThT) (EMD Millipore) to a final concentration of 1 μM.  Samples were 
continuously shaken at 960 RPM on a Varioskan multimode plate reader at 37°C, and fluorescence 
readings were recorded every 15 min or 20 min for 48 h (excitation 444 nm, emission 485 nm).  Assays 
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were run in quadruplicate, in volumes of 200 μL in sealed (Perkin-Elmer), black, clear-bottom 96 well 
plates (Grenier BioOne). 
Crystallographic Studies 
Insulin crystals were obtained from sitting drop trays set using a Mosquito robot (TTP Labtech). Drops 
were set by mixing 0.4 μL insulin solution with 0.4 μL well solution. Cells were cryoprotected in a mother 
liquor containing 30% glycerol prior to looping and flash freezing in liquid nitrogen. Data were collected 
at SSRL beamline BL12-2 using a DECTRIS PILATUS 6M pixel detector. Initial indexing and scaling was 
performed with XDS; for some structures, data were re-scaled in alternative space groups using Aimless4. 
Initial phases were generated by molecular replacement in PHASER with 3T2A (5USV, 5URT, 5UU2, and 
5USP) or 1EV3 (5URU, 5UU4, and 5USS).5 Structure refinement was carried out in Coot and Refmac.6-7 
Data were deposited in the PDB with the following codes: 5USV (T2-AzeI), 5URT (T2-DhpI), 5UU2 (T2-ThzI), 
5USP (T2-PipI), 5URU (R6-DhpI), 5UU4 (R6-ThzI), and 5USS (R6-PipI). All distances and contacts were 
computed using UCSF Chimera Crystallography Software.8 
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Results and Discussion 
Supplemental figures 
FIGURE S1 Insulin expression and incorporation of proline analogs. (A-D) SDS-PAGE of cell lysates with 
lanes labelled for pre-induction (PRE) and post-induction in 19-amino acid minimal media supplemented 
with either nothing (19aa), Aze (A), Dhp (B), Thz (C), or Pip (D), or Pro. (E-I) MALDI-MS traces of isolated 
proinsulin peptide fragment 46RGFFYTPKTRRE57 obtained by gluC digestion. Peptide fragment masses 
correspond to either wild type mass (1558 Da, E) or shifted masses (1544 Da for AzeI, F; 1555 Da for DhpI, 
G; 1575 Da for ThzI, H; or 1571 Da for PipI, I). Inset is whole protein MALDI-MS (instrument error ~10 Da) 
with observed masses: 5799 Da (ProI, E), 5789 Da (AzeI, F), 5800 Da (DhpI, G), 5823 Da (ThzI, H), and 
5812 Da (PipI, I). Ion counts >103 for all MALDI-MS spectra. 
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FIGURE S2 Crystal structures of insulin variants showing the insulin dimer interface. (A-D) Insulin variants 
in the T2 dimer form. (E-H) Structures of insulins in the R6 hexamer form. Human insulin (PDB Code: 1ZNJ) 
in panel E for reference. All images highlight the distance between the γ-carbon of the ring at position B28 
and its closest neighbors, the backbone carbonyl oxygen atoms of GlyB20’ and GluB21’, across the dimer 
interface. 
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Supplemental tables 
TABLE S1 Expression Yields of Proinsulins and Incorporation Levels of Proline Analogs 
B28 Amino Acid Incorporation (%)a Yield (mg/L)b 
Proline (Pro) -- 50 
(S)-azetidine-2-carboxylic acid (Aze) ≤100c 24 
(3,4)-dehydro-L-proline (Dhp) ≤100c 23 
(4S)-1,3-thiazolidine-4-carboxylic acid (Thz) 90 28 
(S)-piperidine-2-carboxylic acid (Pip) 89 21 
a Quantified by MALDI-MS from shake flask expressions: Proinsulin peptide obtained by gluC digestion: 46RGFFYTPKTRRE57. 
b Yield quantified by BCA assay post-refolding at the proinsulin level.   
c The canonical peptide was not detected or uniquely identified in MALDI-MS spectra. 
 
TABLE S2 Data Tables and Refinement Values for the T2 Structures 
 AzeI  DhpI ThzI PipI 
PDB Code 5USV 5URT 5UU2 5USP 
Data collection         
Space group I 2
1
 3 I 2
1
 3 I 2
1
 3 I 2
1
 3 
Cell dimensions         
    a, b, c (Å) 77.979, 77.979, 
77.979 
77.950, 77.950, 
77.950 
78.067, 78.067, 
78.067 
78.047, 78.047, 
78.047 
    𝛼, 𝛽, 𝛾  ()  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 31.83-1.3  
(1.33-1.3) 
55.12-1.17  
(1.19-1.17) 
31.87-1.22  
(1.25-1.22) 
39.02-1.17  
(1.19-1.17) 
R
p.i.m. 
(%) 3.7 (12.1) 2.1 (53.6) 1.6 (25.1) 2.0 (34.2) 
Mn(I /sd) 13.2 (1.2) 18.1 (1.3) 23.5 (3.4) 17.8 (2.0) 
Completeness (%) 99.4 (100) 99.7 (94.6) 99.6 (91.5) 99.75 (93.3) 
Redundancy 18.4 (17.2) 18.6 8.1 (4.5) 10 (5.4) 
Refinement       
No. reflections 26650 (1288) 26449(1328) 23424 (1064) 26485 (1198) 
R
work
 / R
free
 (%) 14.2/15.9 (23.2/23.3) 11.9/14.1 (23.9/27.2) 13.7/15.5 (17.4/22.9) 13.9/15.26 
(20.9/22.3) 
No. atoms     
    Protein 392 397 397 467 
    Ligand/ion 1 1 0 1 
    Water 58 67 68 71 
RMSD       
    Bond lengths (Å) 0.009 0.028 0.017 0.008 
    Bond angles () 1.978 2.273 1.53 1.07 
Ramachandran map analysis     
Favored 50 50 50 50 
Allowed 0 0 0 0 
Outliers 0 0 0 0 
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TABLE S3 Data Tables and Refinement Values for the R6 Structures 
 DhpI ThzI PipI 
PDB Code 5URU 5UU4 5USS 
Data collection      
Space group H 3 H 3 H 3 
Cell dimensions      
    a, b, c (Å) 79.259, 79.259, 
79.874 
78.09, 78.09, 39.93 79.024, 79.024, 
39.509 
    𝛼, 𝛽, 𝛾  ()  90, 90, 120 90, 90, 120 90, 90, 120 
Resolution (Å) 34.52-2.41  
(2.47-2.41) 
39.05-1.96  
(2.01-1.96) 
25.87-2.06 (2.11-
2.06) 
R
p.i.m. 
(%) 4.2 (30.8) 2.2 (14.5) 2.6 (34.2) 
Mn(I /sd) 5.4 (2.1) 19.4 (0.5) 12.9 (3.2) 
Completeness (%) 99.76 (99.6) 98.1 (76.3) 99.8 (99.8) 
Redundancy 4.6 5.5 (3.6) 5.3 (5.0) 
Refinement    
No. reflections 6816 (469) 6396 (350) 9265 (422) 
R
work
 / R
free
 (%) 19.0/23.7 (22.2/28.7) 23.2/26.4 (33.0/36.3) 16.9/23.8 (22.9/30.7) 
No. atoms    
    Protein 1439 661 708 
    Ligand/ion 32 22 18 
    Water 7 0 1 
RMSD    
    Bond lengths (Å) 0.022 0.018 0.008 
    Bond angles () 2.04 1.800 1.047 
Ramachandran map analysis    
Favored 194 93 97 
Allowed 0 1 0 
Outliers 0 0 0 
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